Business Context and Reporting Period
This Form 8-K Current Report is filed by Kalaris Therapeutics, Inc. (KLRS) on July 14, 2026. The report discloses significant changes in the Company's senior financial leadership, specifically the appointment of a new Chief Financial Officer and the resignation of the Chief Accounting Officer.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any operational financial metrics.
Material Changes
Appointment of Chief Financial Officer
- Officer: Liisa Bayko appointed as Chief Financial Officer and Treasurer, effective July 20, 2026.
- Background: Former Managing Director of Biotech Equity Research at Evercore ISI (2020–2025) and JMP Securities (2011–2020).
- Compensation:
- Annualized base salary: $475,000.
- Target annual incentive bonus: Up to 40% of base salary.
- Equity: Grant of 220,000 incentive stock options (vesting 25% after one year, then monthly over 36 months).
- Severance Provisions:
- Standard Termination: 9 months of base salary and health coverage if terminated without cause or for good reason outside the change-in-control window.
- Change in Control: 12 months of base salary, 100% of target bonus, 12 months of health coverage, and full acceleration of unvested time-based equity if terminated within 3 months prior to or 12 months following a change in control.
Resignation of Chief Accounting Officer
- Officer: Brett Hagen resigned as Senior Vice President, Finance and Chief Accounting Officer, effective July 27, 2026.
- Interim Successor: Amy Vandekop, Corporate Controller, designated as interim principal accounting officer effective July 27, 2026.
- Background: Ms. Vandekop has served as Associate Vice President, Corporate Controller since March 2025 (post-AlloVir merger) and previously held senior accounting roles at AlloVir, Lumicell, and KPMG.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business strategy or market conditions. The primary risk disclosed relates to the transition of financial leadership and the potential future liability associated with the new CFO's severance package in the event of a change in control.
Investor Verification Checklist
- Verify the closing stock price on July 20, 2026, to determine the exercise price of the 220,000 options granted to Liisa Bayko.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Confirm the status of the Company's cash reserves to assess the ability to fund the new CFO's compensation and potential severance obligations.
- Monitor subsequent filings for the permanent appointment of a Chief Accounting Officer following the interim designation of Amy Vandekop.